Indexed In
- Academic Journals Database
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- China National Knowledge Infrastructure (CNKI)
- Scimago
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- MIAR
- University Grants Commission
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Articles published in Journal of Vaccines & Vaccination have been cited by esteemed scholars and scientists all around the world. Journal of Vaccines & Vaccination has got h-index 24, which means every article in Journal of Vaccines & Vaccination has got 24 average citations.
Following are the list of articles that have cited the articles published in Journal of Vaccines & Vaccination.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total published articles |
67 | 60 | 59 | 65 | 71 | 11 | 19 | 26 | 45 | 44 | 52 | 59 | 54 | 13 | 14 |
Research, Review articles and Editorials |
14 | 14 | 19 | 41 | 29 | 11 | 15 | 16 | 17 | 34 | 40 | 42 | 38 | 10 | 10 |
Research communications, Review communications, Editorial communications, Case reports and Commentary |
38 | 46 | 40 | 30 | 42 | 0 | 4 | 10 | 28 | 10 | 12 | 17 | 21 | 3 | 4 |
Conference proceedings |
18 | 8 | 32 | 23 | 0 | 0 | 112 | 104 | 154 | 315 | 180 | 116 | 110 | 122 | 0 |
Citations received as per Google Scholar, other indexing platforms and portals |
121 | 206 | 193 | 258 | 232 | 212 | 200 | 205 | 224 | 245 | 110 | 61 | 22 | 20 | 0 |
| Journal total citations count | 2341 |
| Journal impact factor | 2.87 |
| Journal 5 years impact factor | 3.73 |
| Journal cite score | 4.69 |
| Journal h-index | 24 |
Important citations
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and
Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2–17 years: systematic review and meta-analysis
Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries.
Immunogenicity and safety of a tetravalent dengue vaccine during a five-year follow-up period
Systematic review of dengue vaccine efficacy
Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study.
Long-term immunogenicity and safety of tetravalent dengue vaccine (CYD-TDV) in healthy populations in Singapore and Vietnam: 4-year follow-up of randomized, controlled, phase II trials.
Tackling dengue fever: Current status and challenges
A recombinant live attenuated tetravalent vaccine for the prevention of dengue.
Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014).
Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis.
Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials.
Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety.
Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials
Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia.
Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies
Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil